Neuroinflammation in Patients With OCD
Key facts
- Who runs it
- New York State Psychiatric Institute
- Where
- New York, United StatesSee the site
- Trial code
- Status
- Completed
- Phase
- Phase 2
- People taking part
- 18 people enrolled
- Started
- 1 Apr 2021
- Ended
- 28 Oct 2026
- Type of study
- Interventional
- Treatments tested
- Celecoxib
- Record updated
- 30 October 2026
Who can take part
- Age
- 18 years to 55 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- 18 to 55 years old
- Principal diagnosis of Obsessive-Compulsive Disorder (OCD)
- Ongoing OCD symptoms despite current treatment with psychiatric medication
- Capacity to provide informed consent
Who cannot take part
- Contraindications to an MRI or PET scan (e.g., metal implants)
- Current use of medications that may interact with study drug or impact research measures (e.g., antipsychotics, corticosteroids, immunosuppressant medications, or daily non-steroidal anti-inflammatory medications)
- Starting a new evidence-based therapy for OCD (e.g., exposure with response prevention) 4 weeks prior to study enrollment
- Psychiatric comorbidities that would increase risk of participation or impact research measures (e.g., suicidality)
- Medical or neurological conditions that would increase risk of participation or impact research measures
Where in United States
- New York State Psychiatric InstituteNew York, United States
About the trial
What the trial wants to find out
The goal of this study is to examine whether measurements of inflammation from brain scanning and blood tests can predict how much benefit patients with obsessive-compulsive disorder (OCD) will have from treatment with an anti-inflammatory medication, celecoxib, when adding to ongoing medication-based treatment for OCD.
The group in the trial
- Celecoxib TreatmentTreatment being tested
Patients will receive standardized pharmacotherapy with celecoxib 100mg twice daily for the first week, and will then, if well-tolerated, will be increased to 200mg twice daily for the next seven weeks. Visits with the study psychiatrist will occur weekly for the first four weeks, and biweekly thereafter until week 8, which will be conducted remotely in general, although they may be conducted in-person as clinically warranted and may be conducted in person on the days of other in-person visits. If individuals experience significant side-effects from a given dose, the treating physician may lower the medication dose according to clinical judgment; if side-effects are intolerable, we will discontinue the research procedures and advance to open clinical treatment
Treatment: Celecoxib
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Precision Medicine Approach to OCD Treatment: Targeting Neuroinflammation
- Record updated
- 30 October 2026